Mid-regional proadrenomedullin (MR-proADM), C-reactive protein (CRP) and other biomarkers in the early identification of disease progression in patients with COVID-19 in the acute NHS setting.
Nathan A MooreRebecca WilliamsMatilde MoriBeatrice BertolussoGabrielle VernetJessica LynchPete PhilipsonThomas LedgerwoodStephen P KiddClaire ThomasVeronica Garcia-AriasMichelle YoungKordo SaeedKirsty GordonNicholas CortesPublished in: Journal of clinical pathology (2022)
The measurement of MR-proADM and CRP in patients with confirmed COVID-19 infection on admission shows significant potential to support clinicians in identifying those at increased risk of disease progression and need for higher level care, subsequently enabling prompt escalation in clinical interventions.
Keyphrases
- palliative care
- contrast enhanced
- liver failure
- healthcare
- magnetic resonance
- emergency department
- respiratory failure
- patient safety
- quality improvement
- physical activity
- drug induced
- magnetic resonance imaging
- clinical trial
- bioinformatics analysis
- randomized controlled trial
- affordable care act
- hepatitis b virus
- intensive care unit
- health insurance
- mechanical ventilation